Search

Your search keyword '"Nwokolo, Nneka"' showing total 270 results
Start Over Author "Nwokolo, Nneka"
270 results on '"Nwokolo, Nneka"'

5. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Antinori, Andrea, Apea, Vanessa, Asmuth, David, Avery, Ann, Benson, Paul, Bergin, Colm, Berhe, Mezgebe, Brar, Indira, Brinson, Cynthia, Brunetta, Jason, Burack, Jeffrey, Campbell, Thomas, Cespedes, Michelle, Clarke, Amanda, Coleman, Megan, Coll, Josep, Crespo Casal, Manuel, Creticos, Catherine, Crofoot, Gordon, Cruickshank, Frederick, Cua, Eric, Daar, Eric, de Wet, Joseph, DeJesus, Edwin, Del Romero Guerrero, Jorge, Dinges, William, Doblecki-Lewis, Susanne, Donovan, Taylor, Dosekun, Olamide, Flamm, Jason, Gallant, Joel, Gerstoft, Jan, Gilson, Richard, Gladstein, Jay, Grant, Robert, Grossberg, Robert, Haas, Bernhard, Halperin, Jason, Hardy, W. David, Hare, Charles, Hassler, Shawn, Hengel, Richard, Henry, William, Hodge, Theo, Jr., Hosek, Sybil, Hurt, Christopher, Iandiorio, Michelle, Jessen, Heiko, Kegg, Stephen, Knecht, Gabriele, Kronborg, Gitte, Krznaric, Ivanka, LaMarca, Anthony, Larsen, Carsten Schade, Larsen, Olav Ditlevsen, Lazzarin, Adriano, Leen, Clifford, Lucasti, Christopher, Mallon, Patrick, Mannheimer, Sharon, Markowitz, Martin, Martorell, Claudia, Mayer, Kenneth, Mills, Anthony, Molina, Jean-Michel, Morris, Sheldon, Mounzer, Karam, Nwokolo, Nneka, Ogbuagu, Onyema, Osiyemi, Olayemi, Petroll, Andrew, Philibert, Patrick, Phoenix, John, Pialoux, Gilles, Podzamczer, Daniel, Post, Frank, Prins, Maria, Ramgopal, Moti, Rashbaum, Bruce, Reeves, Iain, Richmond, Gary, Rieger, Armin, Ruane, Peter, Salazar, Laura, Scarsella, Anthony, Schembri, Gabriel, Scott, Mia, Shalit, Peter, Sinclair, Gary, Sobieszczyk, Magdalena, Spinner, Christoph, Stephens, Jeffrey, Szabo, Jason, Taylor, Stephen, Thompson, Melanie, Tremblay, Cecile, Trottier, Benoit, Voskuhl, Gene, Wade, Barbara, Wohl, David, Workowski, Kimberly, Yawetz, Sigal, Young, Benjamin, Ruane, Peter J, Salazar, Laura C, Henry, Keith, Asmuth, David M, Shao, Yongwu, Ebrahimi, Ramin, Cox, Stephanie, Kintu, Alexander, Carter, Christoph, Das, Moupali, Baeten, Jared M, Brainard, Diana M, Whitlock, Gary, Brunetta, Jason M, and Spinner, Christoph D

Published
2021
Full Text
View/download PDF

7. Rapid antiretroviral therapy in primary HIV-1 infection enhances immune recovery

Author

Thornhill, John Patrick, primary, Fox, Julie, additional, Martin, Genevieve Elizabeth, additional, Hall, Rebecca, additional, Lwanga, Julianne, additional, Lewis, Heather, additional, Brown, Helen, additional, Robinson, Nicola, additional, Kuldanek, Kristen, additional, Kinloch, Sabine, additional, Nwokolo, Nneka, additional, Whitlock, Gary, additional, Fidler, Sarah, additional, and Frater, John, additional

Published
2023
Full Text
View/download PDF

9. Comorbidities and menopause assessment in women living with HIV: a survey of healthcare providers across the WHO European region.

Author

Caixas, Umbelina, Tariq, Shema, Morello, Judit, Dragovic, Gordana, Lourida, Giota, Hachfeld, Anna, and Nwokolo, Nneka

Subjects
DIABETES risk factors, MEDICAL screening, CARDIOVASCULAR diseases, SURVEYS, RISK assessment, PSYCHOLOGY of women, AGING, DESCRIPTIVE statistics, RESEARCH funding, MENOPAUSE, BONE density, PSYCHOLOGY of HIV-positive persons, COMORBIDITY
Abstract

Women living with HIV are reaching older age and experiencing menopause and age-related comorbidities. Data suggest that women living with HIV experience earlier menopause and more menopausal symptoms and age-related comorbidities compared to women without HIV. However, there are no guidelines on the screening for and management of age-related comorbidities and events in women living with HIV. Moreover, little is known about provision of care to this population across Europe. We surveyed 121 HIV healthcare providers in 25 World Health Organization European countries to ascertain screening practices for, and management of, menopause, psychosocial and sexual well-being and age-related comorbidities in women with HIV. Most respondents screened for diabetes, cardiovascular disease (CVD) risk factors and poor mental health at least annually. Low bone mineral density (BMD) was regularly checked but less than once a year. Fewer regularly screened for sexual well-being and intimate partner violence. Menstrual pattern and menopausal symptoms in women aged 45–54 were assessed by 67% and 59% of respondents. 44% stated that they were not confident assessing menopausal status and/or symptoms. CVD, diabetes, low BMD and poor mental health were managed mainly within HIV clinics, whereas menopause care was mainly provided by gynaecology or primary care. Most respondents stated a need for HIV and menopause guidelines. In conclusion, we found that whilst metabolic risk factors and poor mental health are regularly screened for, psychosocial and sexual well-being and menopausal symptoms could be improved. This highlights the need for international recommendations and clinician training to ensure the health of this population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Predictors of starting and stopping chemsex in men who have sex with men in England: findings from the AURAH2 prospective study

Author

Hammond, Robbie, primary, Cambiano, Valentina, additional, Lampe, Fiona C., additional, Asboe, David, additional, Clarke, Amanda, additional, Gilson, Richard, additional, Hart, Graham J, additional, Miltz, Ada Rose, additional, Nwokolo, Nneka, additional, Johnson, Anne M, additional, Phillips, Andrew N, additional, Speakman, Andrew, additional, Whitlock, Gary, additional, Rodger, Alison, additional, and Sewell, Janey, additional

Published
2023
Full Text
View/download PDF

14. a survey of healthcare providers across the WHO European region

Author

Caixas, Umbelina, Tariq, Shema, Morello, Judit, Dragovic, Gordana, Lourida, Giota, Hachfeld, Anna, Nwokolo, Nneka, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and iNOVA4Health - pólo NMS

Subjects
Social Psychology, SDG 3 - Good Health and Well-being, screening, Public Health, Environmental and Occupational Health, HIV, menopausal hormone therapy, menopause, age-related comorbidities, women, integrated care, Health(social science)
Abstract

FundingThis work was supported by European AIDS Clinical Society. Women living with HIV are reaching older age and experiencing menopause and age-related comorbidities. Data suggest that women living with HIV experience earlier menopause and more menopausal symptoms and age-related comorbidities compared to women without HIV. However, there are no guidelines on the screening for and management of age-related comorbidities and events in women living with HIV. Moreover, little is known about provision of care to this population across Europe. We surveyed 121 HIV healthcare providers in 25 World Health Organization European countries to ascertain screening practices for, and management of, menopause, psychosocial and sexual well-being and age-related comorbidities in women with HIV. Most respondents screened for diabetes, cardiovascular disease (CVD) risk factors and poor mental health at least annually. Low bone mineral density (BMD) was regularly checked but less than once a year. Fewer regularly screened for sexual well-being and intimate partner violence. Menstrual pattern and menopausal symptoms in women aged 45–54 were assessed by 67% and 59% of respondents. 44% stated that they were not confident assessing menopausal status and/or symptoms. CVD, diabetes, low BMD and poor mental health were managed mainly within HIV clinics, whereas menopause care was mainly provided by gynaecology or primary care. Most respondents stated a need for HIV and menopause guidelines. In conclusion, we found that whilst metabolic risk factors and poor mental health are regularly screened for, psychosocial and sexual well-being and menopausal symptoms could be improved. This highlights the need for international recommendations and clinician training to ensure the health of this population. publishersversion epub_ahead_of_print

Published
2023

16. Trends in HIV incidence between 2013-2019 and association of baseline factors with subsequent incident HIV among gay, bisexual, and other men who have sex with men attending sexual health clinics in England: A prospective cohort study

Author

Hanum, Nadia, Cambiano, Valentina, Sewell, Janey, Rodger, Alison J., Nwokolo, Nneka, Asboe, David, Gilson, Richard, Clarke, Amanda, Miltz, Ada R., Collins, Simon, Delpech, Valerie, Croxford, Sara, Phillips, Andrew N., and Lampe, Fiona C.

Subjects
MSM (Men who have sex with men) -- Health aspects -- Behavior, HIV infection -- Risk factors -- Forecasts and trends -- Demographic aspects, Gays -- Health aspects -- Behavior, Market trend/market analysis, Biological sciences
Abstract

Background Prospective cohort studies of incident HIV and associated factors among gay, bisexual, and other men who have sex with men (GBMSM) in the United Kingdom are lacking. We report time trends in and factors associated with HIV incidence between 2013 and 2019 among a cohort of GBMSM: the AURAH2 prospective study. Methods and findings Participants were recruited through 1 of 3 sexual health clinics in London and Brighton (July 2013 to April 2016) and self-completed a baseline paper questionnaire and subsequent 4-monthly and annual online questionnaires (March 2015 to March 2018), including information on sociodemographics, lifestyle, health and well-being, HIV status, sexual/HIV-related behaviours, and preexposure prophylaxis and postexposure prophylaxis (PrEP/PEP). Incident HIV was ascertained by linkage with national HIV surveillance data from Public Health England (PHE). We investigated the associations of HIV incidence with (1) baseline factors using mixed-effects Weibull proportional hazard models, unadjusted and adjusted for age, country of birth and ethnicity, sexuality, and education level; and (2) time-updated factors, using mixed-effects Poisson regression models. In total, 1,162 men (mean age 34 years, 82% white, 94% gay, 74% university-educated) were enrolled in the study. Thirty-three HIV seroconversions occurred over 4,618.9 person-years (PY) of follow-up: an overall HIV incidence rate (IR) of 0.71 (95% confidence interval (CI) 0.51 to 1.00) per 100 PY. Incidence declined from 1.47 (95% CI 0.48 to 4.57) per 100 PY in 2013/2014 to 0.25 (95% CI 0.08 to 0.78) per 100 PY in 2018/2019; average annual decline was 0.85-fold (p < 0.001). Baseline factors associated with HIV acquisition included the following: injection drug use (6/38 men who reported injection drug-acquired HIV; unadjusted conditional hazard ratio (HR) 27.96, 95% CI 6.99 to 111.85, p < 0.001), noninjection chemsex-related drug use (13/321; HR 6.45, 95% CI 1.84 to 22.64, p 10 partners [7/57]; 5 to 10 partners [5/60]; and 2 to 4 partners [11/293]: 14.04, 95% CI 4.11 to 47.98; 9.60, 95% CI 2.58 to 35.76; and 4.05, 95% CI 1.29 to 12.72, respectively, p < 0.001); CLS with HIV-positive partners (14/147; HR 6.45, 95% CI 3.15 to 13.22, p < 0.001), versatile CLS role (21/362; HR 6.35, 95% CI 2.18 to 18.51, p < 0.001), group sex (64/500; HR 8.81, 95% CI 3.07 to 25.24, p < 0.001), sex for drugs/money (4/55, HR 3.27, 95% CI 1.14 to 9.38, p = 0.027) (all in previous 3 months); previous 12-month report of a bacterial sexually transmitted infection (STI) diagnoses (21/440; HR 3.95, 95% CI 1.81 to 8.63, p 100 new partners: 3.17, 95% CI 1.39 to 7.26; 4.40, 95% CI 1.35 to 14.29; and 4.84, 95% CI 1.05 to 22.4, respectively, p < 0.001). Results were broadly consistent for time-updated analysis (n = 622 men). The study's main limitation is that men may not be representative of the broader GBMSM population in England. Conclusions We observed a substantial decline in HIV incidence from 2013 to 2019 among GBMSM attending sexual health clinics. Injection drug use, chemsex use, and measures of high-risk sexual behaviour were strongly associated with incident HIV. Progress towards zero new infections could be achieved if combination HIV prevention including Test and Treat strategies and routine commissioning of a PrEP programme continues across the UK and reaches all at-risk populations., Author(s): Nadia Hanum 1,*, Valentina Cambiano 1, Janey Sewell 1, Alison J. Rodger 1, Nneka Nwokolo 2, David Asboe 2, Richard Gilson 1,3, Amanda Clarke 4, Ada R. Miltz 1, [...]

Published
2021
Full Text
View/download PDF

17. Comorbidities and menopause assessment in women living with HIV: a survey of healthcare providers across the WHO European region

Author

Caixas, Umbelina, Tariq, Shema, Morello, Judit, Dragovic, Gordana, Lourida, Giota, Hachfeld, Anna, and Nwokolo, Nneka

Subjects
610 Medicine & health
Abstract

Women living with HIV are reaching older age and experiencing menopause and age-related comorbidities. Data suggest that women living with HIV experience earlier menopause and more menopausal symptoms and age-related comorbidities compared to women without HIV. However, there are no guidelines on the screening for and management of age-related comorbidities and events in women living with HIV. Moreover, little is known about provision of care to this population across Europe. We surveyed 121 HIV healthcare providers in 25 World Health Organization European countries to ascertain screening practices for, and management of, menopause, psychosocial and sexual well-being and age-related comorbidities in women with HIV. Most respondents screened for diabetes, cardiovascular disease (CVD) risk factors and poor mental health at least annually. Low bone mineral density (BMD) was regularly checked but less than once a year. Fewer regularly screened for sexual well-being and intimate partner violence. Menstrual pattern and menopausal symptoms in women aged 45-54 were assessed by 67% and 59% of respondents. 44% stated that they were not confident assessing menopausal status and/or symptoms. CVD, diabetes, low BMD and poor mental health were managed mainly within HIV clinics, whereas menopause care was mainly provided by gynaecology or primary care. Most respondents stated a need for HIV and menopause guidelines. In conclusion, we found that whilst metabolic risk factors and poor mental health are regularly screened for, psychosocial and sexual well-being and menopausal symptoms could be improved. This highlights the need for international recommendations and clinician training to ensure the health of this population.

Published
2023
Full Text
View/download PDF

18. Eligibility for PrEP among MSM attending GUM clinics in the UK

Author

Miltz, Ada Rose, Cambiano, Valentina, Lampe, Fiona C, Sewell, Janey, Speakman, Andrew, Phillips, Andrew N, Ivens, Daniel R, Asboe, David, Collins, Simon, Brady, Michael, Nwokolo, Nneka C, Rodger, Alison J, Miltz, Ada R, Sewell, Janey, Rodger, Alison J, Speakman, Andrew, Lampe, Fiona C, Phillips, Andrew N, Sherr, Lorraine, Gilson, Richard J, Asboe, David, Nwokolo, Nneka C, Clarke, Amanda, Gompels, Mark M, Allan, Sris, Collins, Simon, Scott, Christopher, Day, Sara, Fisher, Martin, Anderson, Jane, O’connell, Rebecca, Lascar, Monica, Apea, Vanessa, Farazmand, Maneh, Mann, Susan, Dhar, Jyoti, Ivens, Daniel R, Sadiq, S Tariq, Taylor, Stephen, Brady, Michael, Tang, Alan, Dhairyawan, Rageshri, Hart, Graham J, Johnson, Anne M, Miners, Alec, and Elford, Jonathan

Published
2017
Full Text
View/download PDF

21. Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption

Author

Pace, Matthew, primary, Ogbe, Ane, additional, Hurst, Jacob, additional, Robinson, Nicola, additional, Meyerowitz, Jodi, additional, Olejniczak, Natalia, additional, Thornhill, John P., additional, Jones, Mathew, additional, Waters, Anele, additional, Lwanga, Julianne, additional, Kuldanek, Kristen, additional, Hall, Rebecca, additional, Zacharopoulou, Panagiota, additional, Martin, Genevieve E., additional, Brown, Helen, additional, Nwokolo, Nneka, additional, Peppa, Dimitra, additional, Fox, Julie, additional, Fidler, Sarah, additional, and Frater, John, additional

Published
2022
Full Text
View/download PDF

23. Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co‐administration.

Author

Nwokolo, Nneka, Post, Elana, Mageau, A. Savannah, Shah, Rimi, Magee, Mindy, Mannino, Frank, Ackerman, Peter, Clark, Andrew, and Moore, Katy

Subjects
*THROMBOEMBOLISM risk factors, *ANTI-HIV agents, *HORMONE therapy, *GENDER affirming care, *DRUG tolerance, *LIQUID chromatography, *STEROIDS, *ESTROGEN, *CONTRACEPTIVES, *DRUG interactions, *RESEARCH funding, *ORAL contraceptives, *DESCRIPTIVE statistics, *MASS spectrometry
Abstract

Objectives: Fostemsavir, a prodrug of temsavir, is indicated for heavily treatment‐experienced adults with multidrug‐resistant HIV‐1 infection, antiretroviral (ARV) intolerance, or safety considerations. Understanding drug–drug interactions (DDIs) is important in individuals taking fostemsavir with hormonal contraceptives or menopausal or gender‐affirming hormonal therapies. Methods: Effect of temsavir (active moiety) on the pharmacokinetics of ethinyl estradiol (EE) and norethindrone (NET) was evaluated in an open‐label, single‐sequence, four‐cycle, four‐treatment study in 26 healthy female participants (study 206279, NCT02480881). Relevant ARV–contraceptive interaction studies and guideline recommendations were reviewed; that information was then applied to other contraceptive methods and hormone‐based therapies to predict the impact of fostemsavir co‐administration. Results: Temsavir increased EE concentrations by 40% and had no effect on NET concentrations. Fostemsavir co‐administration with hormone therapy is not expected to impact hormone treatment efficacy. Fostemsavir did not impact progestin; therefore, progestin‐only and non‐hormonal contraceptives will not be impacted by fostemsavir. Recommendations for co‐administration of fostemsavir and hormonal contraceptives or menopausal or gender‐affirming hormone therapies are based upon known and predicted DDIs, ensuring adequate hormonal concentrations to maintain the target effect. Conclusions: Applying the results of Study 206279 and other relevant ARV–contraceptive studies, we recommend that when co‐administering fostemsavir with combined oral contraceptives (COCs) and other oestrogen‐based therapies, EE dose should not exceed 30 μg or equivalent, and caution is advised in the case of individuals with risk factors for thromboembolic events. Other oestrogen‐based therapies may be co‐administered with fostemsavir, with monitoring of oestrogen concentrations and appropriate dose adjustments. No impact of fostemsavir on COC efficacy is expected. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Reflections on a specialist HIV menopause service

Author

Chirwa, Mimie, primary, Taghinejadi, Neda, additional, Macaulay, Gabrielle, additional, Mandalia, Sundhiya, additional, Bellone, Claire, additional, Panay, Nicholas, additional, Brum, Roberta, additional, and Nwokolo, Nneka, additional

Published
2022
Full Text
View/download PDF

28. RECENT PERSPECTIVES ON THE LINK BETWEEN MIGRATION, HUMAN RIGHTS AND HIV AMONG WOMEN.

Author

Rosińska, Magdalena, Bociąga-Jasik, Monika, Ayoubi, Nilofar, Kocbach, Piotr, Nwokolo, Nneka, and Kowalska, Justyna D.

Subjects
HIV, HIV infections, HUMAN rights, MEDICAL personnel, COMMUNITIES, WOMEN'S rights
Abstract

Copyright of Epidemiological Review / Przegląd Epidemiologiczny is the property of National Institute of Public Health - National Institute of Hygiene and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022
Full Text
View/download PDF

29. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients

Author

Bracchi, Margherita, primary, Pagani, Nicole, additional, Dalla Pria, Alessia, additional, Milinkovic, Ana, additional, Nwokolo, Nneka, additional, Thomas, Lervina, additional, Mandalia, Sundhyia, additional, Boffito, Marta, additional, and Moyle, Graeme, additional

Published
2021
Full Text
View/download PDF

30. No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach

Author

Alagaratnam, Jasmini, primary, Stöhr, Wolfgang, additional, Toombs, Jamie, additional, Heslegrave, Amanda, additional, Zetterberg, Henrik, additional, Gisslén, Magnus, additional, Pett, Sarah, additional, Nelson, Mark, additional, Clarke, Amanda, additional, Nwokolo, Nneka, additional, Johnson, Margaret A., additional, Khan, Maryam, additional, Hanke, Tomas, additional, Kopycinski, Jakub, additional, Dorrell, Lucy, additional, Fox, Julie, additional, Kinloch, Sabine, additional, Underwood, Jonathan, additional, Pace, Matthew, additional, Frater, John, additional, Winston, Alan, additional, and Fidler, Sarah, additional

Published
2021
Full Text
View/download PDF

32. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Ogbuagu, Onyema, primary, Ruane, Peter J, additional, Podzamczer, Daniel, additional, Salazar, Laura C, additional, Henry, Keith, additional, Asmuth, David M, additional, Wohl, David, additional, Gilson, Richard, additional, Shao, Yongwu, additional, Ebrahimi, Ramin, additional, Cox, Stephanie, additional, Kintu, Alexander, additional, Carter, Christoph, additional, Das, Moupali, additional, Baeten, Jared M, additional, Brainard, Diana M, additional, Whitlock, Gary, additional, Brunetta, Jason M, additional, Kronborg, Gitte, additional, Spinner, Christoph D, additional, Antinori, Andrea, additional, Apea, Vanessa, additional, Asmuth, David, additional, Avery, Ann, additional, Benson, Paul, additional, Bergin, Colm, additional, Berhe, Mezgebe, additional, Brar, Indira, additional, Brinson, Cynthia, additional, Brunetta, Jason, additional, Burack, Jeffrey, additional, Campbell, Thomas, additional, Cespedes, Michelle, additional, Clarke, Amanda, additional, Coleman, Megan, additional, Coll, Josep, additional, Crespo Casal, Manuel, additional, Creticos, Catherine, additional, Crofoot, Gordon, additional, Cruickshank, Frederick, additional, Cua, Eric, additional, Daar, Eric, additional, de Wet, Joseph, additional, DeJesus, Edwin, additional, Del Romero Guerrero, Jorge, additional, Dinges, William, additional, Doblecki-Lewis, Susanne, additional, Donovan, Taylor, additional, Dosekun, Olamide, additional, Flamm, Jason, additional, Gallant, Joel, additional, Gerstoft, Jan, additional, Gladstein, Jay, additional, Grant, Robert, additional, Grossberg, Robert, additional, Haas, Bernhard, additional, Halperin, Jason, additional, Hardy, W. David, additional, Hare, Charles, additional, Hassler, Shawn, additional, Hengel, Richard, additional, Henry, William, additional, Hodge, Theo, additional, Hosek, Sybil, additional, Hurt, Christopher, additional, Iandiorio, Michelle, additional, Jessen, Heiko, additional, Kegg, Stephen, additional, Knecht, Gabriele, additional, Krznaric, Ivanka, additional, LaMarca, Anthony, additional, Larsen, Carsten Schade, additional, Larsen, Olav Ditlevsen, additional, Lazzarin, Adriano, additional, Leen, Clifford, additional, Lucasti, Christopher, additional, Mallon, Patrick, additional, Mannheimer, Sharon, additional, Markowitz, Martin, additional, Martorell, Claudia, additional, Mayer, Kenneth, additional, Mills, Anthony, additional, Molina, Jean-Michel, additional, Morris, Sheldon, additional, Mounzer, Karam, additional, Nwokolo, Nneka, additional, Ogbuagu, Onyema, additional, Osiyemi, Olayemi, additional, Petroll, Andrew, additional, Philibert, Patrick, additional, Phoenix, John, additional, Pialoux, Gilles, additional, Post, Frank, additional, Prins, Maria, additional, Ramgopal, Moti, additional, Rashbaum, Bruce, additional, Reeves, Iain, additional, Richmond, Gary, additional, Rieger, Armin, additional, Ruane, Peter, additional, Salazar, Laura, additional, Scarsella, Anthony, additional, Schembri, Gabriel, additional, Scott, Mia, additional, Shalit, Peter, additional, Sinclair, Gary, additional, Sobieszczyk, Magdalena, additional, Spinner, Christoph, additional, Stephens, Jeffrey, additional, Szabo, Jason, additional, Taylor, Stephen, additional, Thompson, Melanie, additional, Tremblay, Cecile, additional, Trottier, Benoit, additional, Voskuhl, Gene, additional, Wade, Barbara, additional, Workowski, Kimberly, additional, Yawetz, Sigal, additional, and Young, Benjamin, additional

Published
2021
Full Text
View/download PDF

35. Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy

Author

Martin, Genevieve E., primary, Sen, Debattama R., additional, Pace, Matthew, additional, Robinson, Nicola, additional, Meyerowitz, Jodi, additional, Adland, Emily, additional, Thornhill, John P., additional, Jones, Mathew, additional, Ogbe, Ane, additional, Parolini, Lucia, additional, Olejniczak, Natalia, additional, Zacharopoulou, Panagiota, additional, Brown, Helen, additional, Willberg, Christian B., additional, Nwokolo, Nneka, additional, Fox, Julie, additional, Fidler, Sarah, additional, Haining, W. Nicholas, additional, and Frater, John, additional

Published
2021
Full Text
View/download PDF

36. Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses

Author

Yang, Hongbing, primary, Llano, Anuska, additional, Cedeño, Samandhy, additional, von Delft, Annette, additional, Corcuera, Angelica, additional, Gillespie, Geraldine M., additional, Knox, Andrew, additional, Leneghan, Darren B., additional, Frater, John, additional, Stöhr, Wolfgang, additional, Fidler, Sarah, additional, Mothe, Beatriz, additional, Mak, Johnson, additional, Brander, Christian, additional, Ternette, Nicola, additional, Dorrell, Lucy, additional, Sandström, Eric, additional, Darbyshire, Janet, additional, Post, Frank, additional, Conlon, Christopher, additional, Anderson, Jane, additional, Maini, Mala, additional, Peto, Timothy, additional, Sasieni, Peter, additional, Miller, Veronica, additional, Weller, Ian, additional, Babiker, Abdel, additional, Pett, Sarah, additional, Pace, Matthew, additional, Olejniczak, Natalia, additional, Brown, Helen, additional, Robinson, Nicola, additional, Kopycinski, Jakub, additional, Yang, Hongbing, additional, Hanke, Tomáš, additional, Crook, Alison, additional, Kaye, Steven, additional, McClure, Myra, additional, Erlwein, Otto, additional, Lovell, Andrew, additional, Khan, Maryam, additional, Gabrielle, Michelle, additional, Bennett, Rachel, additional, Sy, Aminata, additional, Gregory, Adam, additional, Hudson, Fleur, additional, Russell, Charlotte, additional, Wood, Gemma, additional, Box, Hanna, additional, Kingsley, Cherry, additional, Topping, Katie, additional, Lever, Andrew, additional, Wills, Mark, additional, Fun, Axel, additional, Bandara, Mikaila, additional, Kelly, Damian, additional, Collins, Simon, additional, Markham, Alex, additional, Rauchenberger, Mary, additional, Sowunmi, Yinka, additional, Shidfar, Shaadi, additional, Hague, Dominic, additional, Nelson, Mark, additional, Cerrone, Maddalena, additional, Castrillo Martinez, Nadia, additional, Barber, Tristan, additional, Schoolmeesters, Alexandra, additional, Weaver, Christine, additional, Thunder, Orla, additional, Rowlands, Jane, additional, Higgs, Christopher, additional, Fedele, Serge, additional, Bracchi, Margherita, additional, Thomas, Lervina, additional, Bourke, Peter, additional, Nwokolo, Nneka, additional, Lawrenson, Gaynor, additional, Fiorino, Marzia, additional, Lukha, Hinal, additional, Kinloch-de Loes, Sabine, additional, Johnson, Margaret, additional, Nightingale, Alice, additional, Ngwu, Nnenna, additional, Byrne, Patrick, additional, Cuthbertson, Zoe, additional, Jones, Martin, additional, Fernandez, Tina, additional, Clarke, Amanda, additional, Fisher, Martin, additional, Gleig, Rebecca, additional, Trevitt, Vittorio, additional, Fitzpatrick, Colin, additional, Adams, Tanya, additional, Finnerty, Fiounnuala, additional, Thornhill, John, additional, Lewis, Heather, additional, Kuldanek, Kristin, additional, Fox, Julie, additional, Lwanga, Julianne, additional, Uzu, Hiromi, additional, Lee, Ming, additional, Merle, Simon, additional, O’Rourke, Patrick, additional, Jendrulek, Isabel, additional, Zarko Flynn, Taras, additional, Taylor, Mark, additional, Manuel Tiraboschi, Juan, additional, and Murray, Tammy, additional

Published
2021
Full Text
View/download PDF

37. ENDGAMES

Author

Quigley, Shaun, Colledge, Jonathan, Patel, Shilpa, Gayed, Wade, Bradshaw, Daniel, Nwokolo, Nneka, and Sedgwick, Philip

Published
2012

38. ENDGAMES

Author

Atkinson, Kate, Bradshaw, Daniel M, Nwokolo, Nneka, Sedgwick, Philip, Woolf, R T, and Abdul-Wahab, Alya

Published
2011

39. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study

Author

Mussini, Cristina, Pezzotti, Patrizio, Miro, Jose M., Martinez, Esteban, de Quiros, Juan Carlos Lopez Bernaldo, Cinque, Paola, Borghi, Vanni, Bedini, Andrea, Domingo, Pere, Cahn, Pedro, Bossi, Philippe, De Luca, Andrea, Monforte, Antonella d'Arminio, Nelson, Mark, Nwokolo, Nneka, Helou, Silvia, Negroni, Ricardo, Jacchetti, Gaia, Antinori, Spinello, Lazzarin, Adriano, Cossarizza, Andrea, Esposito, Roberto, Antinori, Andrea, and Aberg, Judith A.

Subjects
Health, Health care industry
Published
2004

43. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

Author

Fidler, Sarah, primary, Stöhr, Wolfgang, additional, Pace, Matt, additional, Dorrell, Lucy, additional, Lever, Andrew, additional, Pett, Sarah, additional, Kinloch-de Loes, Sabine, additional, Fox, Julie, additional, Clarke, Amanda, additional, Nelson, Mark, additional, Thornhill, John, additional, Khan, Maryam, additional, Fun, Axel, additional, Bandara, Mikaila, additional, Kelly, Damian, additional, Kopycinski, Jakub, additional, Hanke, Tomáš, additional, Yang, Hongbing, additional, Bennett, Rachel, additional, Johnson, Margaret, additional, Howell, Bonnie, additional, Barnard, Richard, additional, Wu, Guoxin, additional, Kaye, Steve, additional, Wills, Mark, additional, Babiker, Abdel, additional, Frater, John, additional, Sandström, Eric, additional, Darbyshire, Janet, additional, Post, Frank, additional, Conlon, Christopher, additional, Anderson, Jane, additional, Maini, Mala, additional, Peto, Timothy, additional, Sasieni, Peter, additional, Miller, Veronica, additional, Weller, Ian, additional, Fidler, Sarah, additional, Pace, Matthew, additional, Olejniczak, Natalia, additional, Brown, Helen, additional, Robinson, Nicola, additional, Crook, Alison, additional, Kaye, Steven, additional, McClure, Myra, additional, Erlwein, Otto, additional, Lovell, Andrew, additional, Gabrielle, Michelle, additional, Sy, Aminata, additional, Gregory, Adam, additional, Hudson, Fleur, additional, Russell, Charlotte, additional, Wood, Gemma, additional, Box, Hanna, additional, Kingsley, Cherry, additional, Topping, Katie, additional, Collins, Simon, additional, Markham, Alex, additional, Rauchenberger, Mary, additional, Sowunmi, Yinka, additional, Shidfar, Shaadi, additional, Hague, Dominic, additional, Cerrone, Maddalena, additional, Castrillo Martinez, Nadia, additional, Barber, Tristan, additional, Schoolmeesters, Alexandra, additional, Weaver, Christine, additional, Thunder, Orla, additional, Rowlands, Jane, additional, Higgs, Christopher, additional, Fedele, Serge, additional, Bracchi, Margherita, additional, Thomas, Lervina, additional, Bourke, Peter, additional, Nwokolo, Nneka, additional, Lawrenson, Gaynor, additional, Fiorino, Marzia, additional, Lukha, Hinal, additional, Nightingale, Alice, additional, Ngwu, Nnenna, additional, Byrne, Patrick, additional, Cuthbertson, Zoe, additional, Jones, Martin, additional, Fernandez, Tina, additional, Fisher, Martin, additional, Gleig, Rebecca, additional, Trevitt, Vittorio, additional, Fitzpatrick, Colin, additional, Adams, Tanya, additional, Finnerty, Fiounnuala, additional, Lewis, Heather, additional, Kuldanek, Kristin, additional, Lwanga, Julianne, additional, Uzu, Hiromi, additional, Lee, Ming, additional, Merle, Simon, additional, O'Rourke, Patrick, additional, Jendrulek, Isabel, additional, ZarkoFlynn, Taras, additional, Taylor, Mark, additional, Tiraboschi, Juan Manuel, additional, and Murray, Tammy, additional

Published
2020
Full Text
View/download PDF

44. Levels of Human Immunodeficiency Virus DNA Are Determined Before ART Initiation and Linked to CD8 T-Cell Activation and Memory Expansion

Author

Martin, Genevieve E, primary, Pace, Matthew, primary, Shearer, Freya M, primary, Zilber, Eva, primary, Hurst, Jacob, primary, Meyerowitz, Jodi, primary, Thornhill, John P, primary, Lwanga, Julianne, primary, Brown, Helen, primary, Robinson, Nicola, primary, Hopkins, Emily, primary, Olejniczak, Natalia, primary, Nwokolo, Nneka, primary, Fox, Julie, primary, Fidler, Sarah, primary, Willberg, Christian B, primary, and Frater, John, primary

Published
2019
Full Text
View/download PDF

46. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

Author

Rodger, Alison J, Cambiano, Valentina, Bruun, Tina, Vernazza, Pietro, Collins, Simon, Degen, Olaf, Corbelli, Giulio Maria, Estrada, Vicente, Geretti, Anna Maria, Beloukas, Apostolos, Raben, Dorthe, Coll, Pep, Antinori, Andrea, Nwokolo, Nneka, Rieger, Armin, Prins, Jan M, Blaxhult, Anders, Weber, Rainer, Van Eeden, Arne, Brockmeyer, Norbert H, Clarke, Amanda, Del Romero Guerrero, Jorge, Raffi, Francois, Bogner, Johannes R, Wandeler, Gilles, Gerstoft, Jan, Gutiérrez, Felix, Brinkman, Kees, Kitchen, Maria, Ostergaard, Lars, et al, University of Zurich, and Rodger, Alison J

Subjects
10234 Clinic for Infectious Diseases, 610 Medicine & health, 2700 General Medicine
Published
2019

48. Transmitted antiretroviral drug resistance in treatment naïve HIV‐infected persons in London in 2011 to 2013

Author

Mcfaul, Katie, Lim, Charlotte, Jones, Rachael, Asboe, David, Pozniak, Anton, Sonecha, Sonali, Boffito, Marta, and Nwokolo, Nneka

Subjects
London, England -- Health aspects, Disease transmission -- Statistics, Viral drug resistance -- Statistics, HIV infection -- Statistics -- Drug therapy, Health
Abstract

Introduction: Previously published UK data on HIV transmitted drug resistance (TDR) shows that it ranges between 3 and 9.4% [1,2]. However, there are no recent data from populations where HIV transmission rates are increasing. The aim of this study was to assess the prevalence of TDR in untreated HIV‐infected individuals attending three HIV specialist clinics under the HIV Directorate, Chelsea and Westminster Hospital and based throughout London – the Kobler Clinic, 56 Dean Street and West London Centre for Sexual Health. Methods: We included all patients with a HIV diagnosis, no history of antiretroviral therapy (ART) intake, attending one of the three clinics (Kobler (K), 56 Dean Street (DS) and West London (WL)), between 2011 and 2013 who started antiretrovirals. Reverse transcriptase (RT) and protease region sequencing was performed using Vircotype virtual phenotype resistance analysis. Drug resistance mutations were identified according to Stanford University HIV Drug Resistance Database (http://hivdb.stanford.edu/). Results: Among 1705 HIV‐1‐infected patients enrolled in the study, 1252 were males (919 were MSM), 107 were females and 346 had no gender recorded. Ethnicity was 51.1% white British/Irish/other, 6.1% African, 2.1% Caribbean, 2.8% Asian, 1.3% Indian/Pakistani/Bangladeshi, 4.2%, other, 3.2% not stated, and 29.2% unknown. 547 were from K (84.3% males, 48.3% MSM), 826 were from DS (84.3% males, 71.9% MSM), and 109 from WL (87.2% males, 56.0% MSM), 223 from other sites not specified. 77.5% (1321 of 1705) of patients had baseline viral resistance testing performed. Prevalence of primary resistance in those with a baseline viral resistance test was 13.5% overall: 19.3% in K, 14.9% in DS, and 14.7% in WL. The most common mutations detected were: NRTI: 184V, 215F, 41L; NNRTI 103N, 179D, 90I; PI 90M, 46I, and 82A. Among patients who tested with TDR, 79.1% had one single mutation, 18.7% and 2.2% exhibited dual or triple class‐resistant viruses, respectively. Conclusions: This study across a large HIV Medicine Directorate reported an overall TDR prevalence which is higher than that previously published and with significant rates of NNRTI resistance at baseline., References Geretti AM, Booth C, Labbett WA, Murphy G, Johnson M. Antivir Ther. 10, Suppl 1:S131 (abstract no. 118). Payne BA, Nsutebu EF, Hunter ER, Olarinde O, Collini P, Dunbar [...]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results